Sees FY25 adjusted EBITDA loss $60M-$65M. Sees FY25 gross margin 48%. Leproust continued, “As we head into fiscal 2025, we’re building on this momentum as we continue our final push toward achieving adjusted EBITDA breakeven while investing in research and development to deliver precision, efficiency and scalability in products and services that continue to generate profitable growth.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience reports Q4 EPS (59c), consensus (69c)
- Twist Bioscience sees Q1 revenue $87M, consensus $84.27M
- Options Volatility and Implied Earnings Moves Today, November 18, 2024
- Absci, Twist Bioscience collaborate to design antibody using generative AI
- Xoma enters $15M royalty monetization arrangement with Twist Bioscience